Inclusion Criteria:

          -  Male or female ≥ 18 years of age

          -  Histologically or cytologically confirmed CRC that is metastatic

          -  Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to
             screening and confirmed by central laboratory

          -  Evidence of measurable disease as per RECIST, v1.1

          -  Subject able to receive cetuximab as per approved label with regards to RAS status

          -  ECOG Status 0 or 1

          -  Adequate renal, hepatic, cardiac and bone marrow functions and adequate electrolytes
             as per protocol

          -  Subject able to take oral medications

        Exclusion Criteria:

          -  Prior systemic therapy for metastatic disease

          -  Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti-EGFR
             inhibitors

          -  Symptomatic brain metastasis or Leptomeningeal disease

          -  History or current evidence of Retinal Vein Occlusion (RVO) or current risk factors
             for RVO

          -  History of chronic inflammatory bowel disease or Crohn's disease requiring medical
             intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12
             months prior to first dose.

          -  Impaired cardiovascular function or clinically significant cardiovascular diseases:
             history of myocardial infarction or coronary disorders within 6 months prior to start
             of study treatment, symptomatic congestive heart failure (grade 2 or higher), past or
             current clinically significant arrhythmia and/or conduction disorder within 6 months
             prior to study treatment start

          -  History of thromboembolic or cerebrovascular events within 6 months prior to start of
             study treatment

          -  Concurrent neuromuscular disorder that is associated with potential elevation of
             Creatine Kinase

          -  Known contraindication to cetuximab administration as per SPC/approved label